Unilife recently announced an agreement with Sanofi to be the sole provider for a minimum of 15 years of cartridge based wearable injectors for all of Sanofi’s large dose volume drugs, excluding insulin. While the details are confidential, it is anticipated that it is for a "fast track" drug for high cholesterol, Alirocumab, which is co- developed by Sanofi and Regeneron. It is pending FDA approval and expected to be commercialized in the June 2015 quarter.
Griffin Securities called this deal a total game changer for Unilife and indicated in its report that even average volume and new-product launches would be enough in net income to drive the stock to its $13.50 price target. They estimate this one wearable injector deal might be enough to bring in $1 billion in annual sales. Digging into their report, they forecast UNIS to be EPS positive in Q4 2015 (June).
This is a good company to keep on watch and get on the ground floor of a potential medical device behemoth in the making. Future earnings reports will confirm.
Griffin Securities called this deal a total game changer for Unilife and indicated in its report that even average volume and new-product launches would be enough in net income to drive the stock to its $13.50 price target. They estimate this one wearable injector deal might be enough to bring in $1 billion in annual sales. Digging into their report, they forecast UNIS to be EPS positive in Q4 2015 (June).
This is a good company to keep on watch and get on the ground floor of a potential medical device behemoth in the making. Future earnings reports will confirm.